Related Experiment Video
Updated: Jan 25, 2026

Monitoring Conformational Dynamics of Single Unmodified Proteins using Plasmonic Nanotweezers
Published on: March 21, 2025
Protocatechualdehyde reduces myocardial fibrosis by directly targeting conformational dynamics of collagen
Yan-Jun Wan1, Qiang Guo1, Dan Liu2
1State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
Abstract:
Myocardial fibrosis is associated with cardiovascular remodeling, which is characterized by abnormal collagen architecture. However, there are not yet effective strategies targeting this abnormal pathological process. The purpose of our study is to investigate the effect of protocatechualdehyde (PCA) on myocardial fibrosis for exploring the underlying target protein and molecular mechanism. We found PCA significantly suppressed isoprenaline (ISO)-induced fibrosis and collagen deposition in myocardial tissue. Then, the direct pharmacological target of PCA was identified as collagen I using cellular thermal shift assay (CETSA) coupled with stable isotope labeling with amino acids in cell culture (SILAC) technology. Surface plasmon resonance (SPR) analysis further confirmed the specific binding of PCA with collagen I. Moreover, collagen self-assembly assay and atomic force microscope analysis confirmed that PCA directly modulated collagen conformational dynamics. LC-MS/MS analysis was applied to determine lysine residues as the binding sites of PCA on collagen I by covalently cross-linking reaction. Collectively, our study suggests that PCA controls cardiovascular remodeling by mediating diffuse interstitial myocardial fibrosis. Moreover, directly targeting collagen may be a promising strategy for the treatment of heart failure and resultant myocardial fibrosis.
Insights
Protocatechualdehyde (PCA) effectively reduces myocardial fibrosis and collagen buildup in heart tissue. This study identifies collagen I as PCA's direct target, suggesting a new therapeutic strategy for heart failure.
Area of Science:
- Cardiovascular Science
- Biochemistry
- Pharmacology
Background:
- Myocardial fibrosis, marked by abnormal collagen, drives cardiovascular remodeling.
- Current strategies for treating myocardial fibrosis remain limited.
Purpose of the Study:
- To investigate the anti-fibrotic effects of protocatechualdehyde (PCA).
- To identify PCA's molecular target and mechanism in myocardial fibrosis.
Main Methods:
- Isoprenaline (ISO)-induced fibrosis model in myocardial tissue.
- Cellular thermal shift assay (CETSA) and SILAC to identify PCA's target.
- Surface plasmon resonance (SPR) for binding confirmation.
- Collagen self-assembly, atomic force microscopy, and LC-MS/MS for mechanism elucidation.
Main Results:
- PCA significantly suppressed ISO-induced myocardial fibrosis and collagen deposition.
- Collagen I was identified as the direct pharmacological target of PCA.
- PCA directly modulated collagen conformational dynamics and identified lysine residues as binding sites.
Conclusions:
- PCA mitigates cardiovascular remodeling by targeting diffuse interstitial myocardial fibrosis.
- Directly targeting collagen represents a promising therapeutic approach for heart failure and associated fibrosis.
Related Concept Videos
Conformity
Conformations of Butane
Conformations of Cycloalkanes
Conformations of Cyclohexane
The chair form is the most stable and derives its name from its resemblance to the “easy chair.” In the chair conformation, two carbon atoms are arranged out-of-plane — one above and one below, minimizing the torsional strain. In the chair form, the bond angle is very close to the ideal...
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...

